Dolutegravir

Dolutegravir: Comprehensive Patient Guide

1. Basic Product Information

2. Mechanism of Action

Simplified Explanation: Dolutegravir is an antiretroviral medicine used to treat HIV-1 infection. It works by blocking an enzyme called “integrase” that the HIV virus needs to multiply in the body. Without this enzyme, the virus cannot copy itself and infect more cells.

For Specialists: Dolutegravir is a potent HIV-1 integrase strand transfer inhibitor (INSTI). It binds to the active site of the viral integrase, blocking the integration of viral DNA into the host genome, a critical step in HIV replication. This action reduces viral load and promotes immune recovery.

3. Pharmacokinetics

• Absorption: Well-absorbed orally; peak blood level is usually reached within 2–3 hours after dosing.
• Distribution: Widely distributed throughout the body, including the cerebrospinal fluid.
• Metabolism: Primarily metabolised in the liver by UGT1A1, with a minor contribution of CYP3A4.
• Elimination: Excreted mostly in faeces (53%) and urine (31%) as metabolites.
• Half-life: Approximately 14 hours, allowing for once-daily dosing in most patients.
• Duration: Once-daily dosing maintains effective concentrations over 24 hours.

4. Use in Everyday Life and Best Practices

Dolutegravir is a core component of modern HIV treatment, usually taken in the morning or evening as directed by your doctor. It can be used alone or in combination with other antiretroviral medicines, commonly as part of combination tablets for convenience.

• Typical Adult Dose: 50 mg once daily, with or without food. In combination therapy, follow the dosing instructions of your prescribed medicine.
• Pediatric Use: Dose is weight-based. Children over 6 years and at least 14 kg may be eligible; consult specialist advice.
• *Do not change your dose or stop taking Dolutegravir without consulting your doctor.*
• Missed Dose: Take as soon as you remember, unless it’s almost time for your next dose. Do not double up.

5. Dosing: Morning vs Evening

• Morning dosing: May reduce the risk of insomnia, as some people report trouble sleeping when taking Dolutegravir late in the day.
• Evening dosing: May suit those with long-standing routines, but discuss with your doctor if you experience disturbed sleep.

Choose a dosing time you can stick to reliably, as regularity is key to effective HIV control. Set a daily alarm or link your medication to a regular activity (e.g. breakfast).

6. Taking with Food or on an Empty Stomach

• Dolutegravir can be taken with or without food; however, taking it with food can further reduce the risk of stomach upset and may improve absorption.
• High-calcium or high-iron meals, common in English diets (e.g. dairy, fortified cereals), may affect absorption if not correctly spaced.
• To avoid issues, separate Dolutegravir from antacids, calcium, or iron supplements by at least 2 hours before or 6 hours after your dose, unless taken with a meal.

7. Interaction Warnings

8. Indications

9. Dosing According to Clinical Indications

10. Safety Profile / Side Effects

Dolutegravir is generally well tolerated. Most side effects are mild and resolve with continued therapy.

If you develop any signs of allergic reaction, severe rash, or liver problems, seek urgent medical advice. Let your GP or pharmacist know of any side effects that bother you or do not go away.

11. Guidelines for Proper Use (Australia Context)

• Take your medication at the same time each day.
• Store at room temperature, away from heat, moisture, and direct sunlight.
• Do not share your medicine with others.
• Keep out of the reach of children.
• Attend all scheduled check-ups and blood tests as directed by your healthcare team.
• If travelling within Australia, bring enough supply and a copy of your script, as pharmacies may need proof for early dispensing under PBS regulations.
• If you have questions about missed doses or side effects, contact your GP, clinical nurse, or authorised pharmacist.

12. Alternative Treatment Options

• Bictegravir (e.g. in Biktarvy®): Another INSTI, available as single-tablet regimens. Similar efficacy, favourable side effect profile.
• Raltegravir (Isentress®): Older INSTI, may require twice-daily dosing in some cases.
• Efavirenz (Atripla®, generics): Non-INSTI, effective but may cause more CNS side effects.
• Darunavir (Prezista®, in Symtuza®): PI-based regimens, useful for resistance but more pill burden and food requirements.

All above are listed on the PBS and may be reimbursed for eligible patients. Your specialist will consider latest guidelines, drug resistance, side effect profile, and your personal preferences.

13. Legal, Registration, and Reimbursement Status in Australia

• Registration: Dolutegravir is registered with the Therapeutic Goods Administration (TGA) for HIV-1 infection.
• Reimbursement: PBS-listed for adults and children with HIV-1, subject to relevant restrictions. Combination forms (Triumeq®, Juluca®, Dovato®) are also PBS-listed.
• Prescription Requirements: Schedule 4 (Prescription Only); available from community and hospital pharmacies in Australia.
• Dispensing: Usually up to one month’s supply at a time under the PBS. Early supply possible for travel/exceptional circumstances with supporting documentation.

14. Latest Research & Clinical Guidance (2022–2025)

• Clinical Trials: Recent studies confirm Dolutegravir’s role as a foundation of first-line ART (ref: IAS-USA Guidelines 2022; EACS 2023).
• Efficacy: Dolutegravir-based regimens maintain high rates of viral suppression and immunological recovery, with a favourable resistance profile (Lancet HIV 2023, 2024).
• Pediatric Use: Supported for children ≥6 years by 2022 TGA and global guidelines based on ODYSSEY and IMPAACT trial findings.
• Pregnancy: Recent safety reviews (NEJM 2023) confirm that Dolutegravir can be used throughout pregnancy, following discussion with your care team.

15. Availability and Delivery

16. FAQ – Common Patient Questions

1. Can I take Dolutegravir with my breakfast tea or coffee?
   Yes, Dolutegravir does not interact with tea or coffee. However, if you are using milk or taking calcium supplements, remember to space out such products as per the guidance above.
2. What happens if I miss a dose?
   If you remember within 12 hours of your usual time, take the missed dose immediately. If it is less than 12 hours to your next dose, skip and resume your usual schedule. Do not double dose.
3. Are there foods I must avoid?
   No, but be aware of high-calcium or high-iron supplements or foods, as these can reduce Dolutegravir absorption unless taken together with a meal.
4. Can Dolutegravir cure HIV?
   No, but when taken as prescribed, it can control HIV, reduce your viral load to undetectable levels, improve immune function, and prevent transmission.
5. Is Dolutegravir safe in pregnancy?
   Yes, new research supports continued use in pregnancy. Always consult your healthcare provider to discuss the best treatment plan for you and your baby.

If you have any other questions, please consult your GP, pharmacist, or HIV care specialist. Keeping up with regular medication and appointments offers the best chance for long-term, healthy living with HIV.